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(b-d) The plasmid pAAV/HBV1.2 (8 g) was hydrodynamically injected into 4-5 week old C57BL/6 mice via the tail vein to obtain an HBV-persistent mouse model. Four weeks later, the HBsAg level in the serum was measured, and mice with 500 ng/mL of serum HBsAg level were defined as HBV-persistent mice. In HBV-persistent mice, the HBsAg and PD-L1 in liver tissue in HBV-persistent mice and HBV-negative (e.g. HBV-eliminated) mice was analyzed by immunohistochemistry (b). The PD-L1 on hepatocytes was analyzed by FACS (c). The serum levels of HBsAg and HBeAg were analyzed by ELISA, HBV-DNA level was analyzed by q-RT-PCR (d). The relationship between the PD-L1 on hepatocytes and the serum HBsAg, HBeAg or HBV DNA was analyzed (e). Data are expressed as the mean±SD from at least three separate experimentswith six mice per group. Significant differences calculated using unpaired two-tailed student's t tests. *P < 0.05, ***P < 0.001. The pEGFP-Pd-l1 expression vector was hydrodynamically injected into 5-6 week old C57BL/6 mice via the tail vein; four weeks later, the Pd-l1 level in liver tissue was analyzed via immunohistochemistry (f), the percentages of hepatic CD69 + and IFN- + CD8 + T cells were detected via FACS (g), and the apoptosis of hepatic CD8 + T cells was analyzed via the double staining of Annexin V and PI and analyzed by FACS (h). The data are representative of three independent experiments with six mice per group. Significant differences calculated using unpaired two-tailed student's t tests. *P< 0.05, versus HBV-mice, IgG, or pEGFP. 
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